Ikaria, Inc. (IKAR) Files $200M IPO
Tweet Send to a Friend
Ikaria, Inc. (Nasdaq: IKAR) filed a registration statement with the U.S. Securities and Exchange Commission for an initial public offering of its common stock. The proposed maximum aggregate offering price is $200 million. The company plans to list on the NASDAQ Global Market under the symbol "IKAR."
The offering is being made through Goldman Sachs, Morgan Stanley, Credit Suisse, Lazard Capital Markets, Cowen & Co., and Wedbush PacGrow Life Sciences.
Ikaria is a fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the significant unmet medical needs of critically ill patients.
The offering is being made through Goldman Sachs, Morgan Stanley, Credit Suisse, Lazard Capital Markets, Cowen & Co., and Wedbush PacGrow Life Sciences.
Ikaria is a fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the significant unmet medical needs of critically ill patients.
You May Also Be Interested In
- UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through
- UPDATE: Lazard Capital Downgrades Vivus (VVUS) to Neutral
- Dan Loeb Builds Massive Stake in Sony (SNE), Wants Entertainment Arm Split
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit Suisse, Morgan Stanley, Lazard, Cowen & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
